Business
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumorsNEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhib
About this update from Indaptus Therapeutics, Inc.
[{"type":"image","alt":"Indaptus Therapeutics","displaySize":"","headline":null,"caption":"Indaptus Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":226,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/9c09e008af85eb0969fb44cb8570a245"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BUI5bQ5PWkG2QG7XsTNFvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9c09e008af85eb0969fb44cb8570a245","width":226,"height":60}},"lazy":false},{"type":"text","content":"New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumors","length":101,"tagName":"p"},{"type":"text","content":"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.","length":506,"tagName":"p"},{"type":"text","content":"Jeffrey Meckler, CEO of Indaptus, commented, “This marks a pivotal step forward for Indaptus and our Decoy platform. Preclinical research has consistently shown that Decoy20 works synergistically with a checkpoint inhibitor, and we now have the opportunity to test that in patients for the first time. While this initial phase will focus on safety and tolerability, we are laying the groundwork for what could be a game-changing approach to treating solid tumors. This combination trial is not just a milestone – it’s an opportunity to showcase our platform’s versatility and move one step closer to improving patient outcomes.”","length":628,"tagName":"p"},{"type":"text","content":"Checkpoint inhibitors such as tislelizumab have improved outcomes in a variety of cancers but many patients still do not respond or ultimately do not experience a long-lasting effect. Decoy20 is engineered to activate the immune system in a manner that is theorized to significantly enhance and broaden the effectiveness of checkpoint inhibitors.","length":346,"tagName":"p"},{"type":"text","content":"About the Combination Trial","len...